Paradigm Biocapital Advisors LP: REVOLUTION MEDICINES INC (RVMD): Quarterly 13F Position History
As of Q2 2026, Paradigm Biocapital Advisors LP reported 6,361,323 shares of REVOLUTION MEDICINES INC (RVMD), worth $1.2B and representing 22.3% of its 13F equity book. Quarter-over-quarter share count change: 294,380 (-4.4%) . The position first appeared in Q1 2024 and has been disclosed across 10 13F-HR filings in Pactolio's tracked window.
- 6,361,323Shares Held (Latest Filing)
- $1.2BReported Market Value (Latest Filing)
- 22.3%Portfolio Weight (% of 13F Equity Book)
- 294,380Quarter-over-Quarter Share Change
- +$544.1MQuarter-over-Quarter Value Change
- 6,655,703Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 10 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 6,361,323 | 294,380 | -4.4% | $1.2B | 22.3% | $187.3 |
| Q1 2026 | 6,655,703 | +11,300 | +0.2% | $647.3M | 13.2% | $97.3 |
| Q4 2025 | 6,644,403 | +421,112 | +6.8% | $529.2M | 14.2% | $79.7 |
| Q3 2025 | 6,223,291 | +130,000 | +2.1% | $290.6M | 8.6% | $46.7 |
| Q2 2025 | 6,093,291 | 84,820 | -1.4% | $224.2M | 9.6% | $36.8 |
| Q1 2025 | 6,178,111 | 375,000 | -5.7% | $218.5M | 10.1% | $35.4 |
| Q4 2024 | 6,553,111 | +1,239,022 | +23.3% | $286.6M | 10.0% | $43.7 |
| Q3 2024 | 5,314,089 | +55,000 | +1.0% | $241.0M | 8.4% | $45.4 |
| Q2 2024 | 5,259,089 | +2,344,114 | +80.4% | $204.1M | 7.8% | $38.8 |
| Q1 2024 | 2,914,975 | – | – | $93.9M | 3.3% | $32.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a RVMD position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported REVOLUTION MEDICINES INC (RVMD) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 10 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in RVMD?
Between Q1 2026 and Q2 2026, Paradigm Biocapital Advisors LP reduced its RVMD position by 294,380 shares (-4.4%), leaving 6,361,323 shares at a market value of $1.2B.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in RVMD?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.